Press release
Nanoform shortlisted for the European Small and Mid-Cap Awards 2021
Nanoform is honoured to be considered for this category, which in particular recognises its growth potential following its IPO.
The Awards, launched in 2013, were established by the
Nanoform, listed on Nasdaq, was shortlisted from some 27 nominations from 17 countries, listed on different European stock exchanges.
The winner is decided by an independent, high-level jury, moderated by the
Florence Bindelle, the Secretary General of EuropeanIssuers, said:
Supporting small and medium enterprises and equity financing is essential to fuel
It is fantastic to see companies like Nanoform excel and grow after having listed on Nasdaq. Innovation is at the core of the European economy. Showcasing Europe's Stars of Innovation is a great way to commend and promote the work of our most innovative newly-listed small and mid-caps, and we congratulate Nanoform on making the shortlist.
About the European Small and Mid-Cap Awards
The objective of the Awards is to promote best practices and highlight the best European Small and Mid-Sized Companies that have gained access to capital markets via an Initial Public Offering (IPO). They showcase the diversity of European markets and aim to promote stock listings, in particular targeting SMEs and growth companies. These companies are critical to accomplishing the EU's goals of job creation, competitiveness, and growth. The European Small and Mid-Cap Awards advocate the benefits of equity financing and encourage smaller companies to consider this financing option. Equity market financing plays a key role in the creation of jobs and growth and in the overall competitiveness of a company. https://europeansmallandmidcapawards.eu
About the
The Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs (DG GROW) of the
About EuropeanIssuers
EuropeanIssuers is a pan-European organisation representing the interests of publicly quoted companies across
About FESE
For further information, please contact:
christian.jones@nanoform.com / +44 7804 474 771
For investor relations queries, please contact:
hvh@nanoform.com / +46 7686 650 11
About Nanoform
Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform's platform technologies. The company focuses on reducing clinical attrition and on enhancing drug molecules' performance through its nanoforming technologies and formulation services. Nanoform's capabilities include GMP manufacturing, and its services span the small to large molecule development space with a focus on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in
https://news.cision.com/nanoform/r/nanoform-shortlisted-for-the-european-small-and-mid-cap-awards-2021,c3420493
https://mb.cision.com/Main/18905/3420493/1472287.pdf
(c) 2021 Cision. All rights reserved., source